Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | MicrobiomeTrials← Back to trialsNCT06428396
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-11-27Est. Completion: 2027-05-05
Enrollment target: 120 participants Locations- City of Hope - Phoenix ( Site 0006), Goodyear, Arizona, United States
- Cedars Sinai Medical Center ( Site 0012), Beverly Hills, California, United States
- Moores Cancer Center at UC San Diego Health ( Site 0025), La Jolla, California, United States
- USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California, United States
- USC Norris Oncology Hematology Newport Beach ( Site 0029), Newport Beach, California, United States
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia, United States
- Southeastern Regional Medical Center ( Site 0010), Newnan, Georgia, United States
- CHRISTUS Highland ( Site 0005), Shreveport, Louisiana, United States
- Renown Regional Medical Center ( Site 0018), Reno, Nevada, United States
- MD Anderson Cancer Center at Cooper ( Site 0024), Camden, New Jersey, United States
- MD Anderson ( Site 0015), Houston, Texas, United States
- Mays Cancer Center ( Site 0022), San Antonio, Texas, United States
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0034), Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Breast CancerSolid Tumor
This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of…
Boston, United StatesEst. completion Dec 31, 2026
Metastatic Breast Cancer
The objective of this non-interventional multicenter study is to provide prospective, observational data on patients ini…
Alexandria, EgyptCompleted Apr 29, 2025
Medical College of Wisconsin - Froedtert Hospital ( Site 0014), Milwaukee, Wisconsin, United StatesCentro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), CABA, Buenos Aires, ArgentinaHospital Británico de Buenos Aires-Oncology ( Site 0500), Ciudad Autónoma de Buenos Aires, Buenos Aires, ArgentinaInstituto de Investigaciones Clínicas Mar del Plata ( Site 0502), Mar del Plata, Buenos Aires, ArgentinaInstituto Alexander Fleming-Alexander Fleming ( Site 0505), Buenos Aires, Buenos Aires F.D., ArgentinaSanatorio Allende - Cerro-Oncology ( Site 0506), Córdoba, Córdoba Province, ArgentinaInstituto de Oncología de Rosario ( Site 0501), Rosario, Santa Fe Province, ArgentinaHospital Italiano de Córdoba ( Site 0508), Córdoba, ArgentinaJewish General Hospital ( Site 0400), Montreal, Quebec, CanadaCentro de Investigación del Maule ( Site 4106), Talca, Maule Region, ChileFALP ( Site 4102), Santiago, Region M. de Santiago, ChilePontificia Universidad Catolica de Chile ( Site 4108), Santiago, Region M. de Santiago, ChileBradfordhill ( Site 4100), Santiago, Region M. de Santiago, ChileIMAT S.A.S ( Site 1205), Montería, Departamento de Córdoba, ColombiaOncologos Del Occidente ( Site 1200), Pereira, Risaralda Department, ColombiaFundacion Valle del Lili ( Site 1204), Cali, Valle del Cauca Department, ColombiaSeoul National University Hospital ( Site 3100), Seoul, South KoreaSamsung Medical Center ( Site 3101), Seoul, South KoreaNational Cheng Kung University Hospital ( Site 3300), Tainan, TaiwanNational Taiwan University Hospital ( Site 3301), Taipei, TaiwanNational Taiwan University Cancer Center ( Site 3302), Taipei, TaiwanFaculty of Medicine Siriraj Hospital ( Site 3500), Bangkoknoi, Bangkok, ThailandFaculty of Medicine - Khon Kaen University ( Site 3502), Muang, Changwat Khon Kaen, ThailandSongklanagarind Hospital ( Site 3501), Hat Yai, Changwat Songkhla, ThailandThe Royal Cornwall Hospital ( Site 1904), Truro, England, United KingdomSt Bartholomews Hospital ( Site 1900), London, London, City of, United KingdomThe Christie Hospital NHS Foundation Trust ( Site 1902), Withington, Manchester, United KingdomIpswich Hospital ( Site 1911), Ipswich, Suffolk, United KingdomPhase 2
Recruiting
HER2-positive Breast Cancer
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecita…
Clayton, AustraliaEst. completion May 1, 2029